Key challenges with implementing gene therapies in clinical practice for hemophilia 

In this interview, Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, gives an overview of the key challenges with implementing gene therapies in clinical practice for patients with hemophilia. First, there are security concerns which can come from patients themselves, or from the fact that clinical trials often don’t include patients with comorbidities or children, and often lack long-term follow-ups. Additionally, gene therapies raise ethical concerns. Finally, these treatments are often very costly and highly technical, which means that not all patients that could benefit from them can afford or access them. This interview took place at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.